You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MIBC

Showing 1 - 25 of 133
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Muscle-Invasive Bladder Carcinoma, Bladder Cancer Trial in Tampa (CG0070, Nivolumab)

Recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Bladder Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Nov 11, 2022

Bladder Cancer Trial in Japan (drug, procedure, radiation)

Not yet recruiting
  • Bladder Cancer
  • Kobe, Hyogo, Japan
  • +3 more
May 26, 2023

Bladder Cancer Trial in Athens (Nivolumab, chemoradiotherapy)

Recruiting
  • Bladder Cancer
  • Nivolumab
  • chemoradiotherapy
  • Athens, Attica, Greece
    Hellenic GenitoUrinary Cancer Group
Mar 22, 2022

Muscle Invasive Bladder Carcinoma Trial (FL-101)

Withdrawn
  • Muscle Invasive Bladder Carcinoma
  • (no location specified)
Aug 17, 2022

Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma Trial (Pembrolizumab)

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • +2 more
  • Indianapolis, Indiana
  • +1 more
Jan 12, 2023

Bladder Cancer Trial in Switzerland (Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), Atezolizumab, Cisplatin)

Recruiting
  • Bladder Cancer
  • Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
  • +3 more
  • Baden, Switzerland
  • +9 more
Aug 12, 2022

Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy Trial in Shanghai (Disitamab Vedotin and Toripalimab)

Recruiting
  • Muscle Invasive Bladder Cancer
  • +4 more
  • Disitamab Vedotin and Toripalimab
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Jul 31, 2023

Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma Trial in Cleveland (Sacituzumab

Not yet recruiting
  • Localized Muscle Invasive Bladder Urothelial Carcinoma
  • Muscle-Invasive Bladder Carcinoma
  • Sacituzumab govitecan
  • Adaptive Radiotherapy
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Apr 18, 2023

Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Neoadjuvant Chemo Trial in Yangsan (dose dense MVAC with pegylated GCSF)

Recruiting
  • Muscle Invasive Bladder Cancer
  • +2 more
  • dose dense MVAC with pegylated GCSF
  • Yangsan, Gyeongsangnam-do, Korea, Republic of
    Pusan National University Yangsan Hospital
Feb 2, 2022

To Better Understand Most Important Factors for Patients When

Recruiting
  • Muscle Invasive Bladder Cancer
  • +4 more
  • Discrete Choice Experiment (DCE) Patients DCE Questionnaire
  • Semi-Structured Interview Patients Interview
  • London, United Kingdom
    Guy's and St Thomas' NHS Foundation Trust
Oct 20, 2022

Muscle Invasive Bladder Cancer Trial in Boston, Minneapolis, Salt Lake City (Nivolumab, Cisplatin, Gemcitabine)

Completed
Has Results
  • Muscle Invasive Bladder Cancer
  • Boston, Massachusetts
  • +2 more
Nov 18, 2021

Muscle-Invasive Bladder Carcinoma, Oligometastatic Disease Trial (metastasis directed therapy (MDT), Immunotherapy)

Recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Metastasis directed therapy (MDT)
  • +2 more
  • Ghent, Belgium
    Ghent University Hospital
Dec 3, 2022

Bladder Cancer, Bladder Tumors, Bladder Tumors Trial in Beijing (Pembrolizumab)

Recruiting
  • Bladder Cancer
  • +4 more
  • Beijing, Beijing, China
    Peking University First Hospital
Dec 18, 2021

Clinical Utility of VI-RADS in Diagnosis of MIBC

Active, not recruiting
  • Radical Cystectomy
  • +3 more
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Oct 24, 2021

    Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma Trial in Houston

    Recruiting
    • Breast Inflammatory Carcinoma
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 27, 2022

    Muscle Invasive Bladder Cancer Trial in New York, Shanghai (APL-1202 in combination with tislelizumab, Tislelizumab alone)

    Recruiting
    • Muscle Invasive Bladder Cancer
    • APL-1202 in combination with tislelizumab
    • Tislelizumab alone
    • New York, New York
    • +1 more
    Feb 21, 2022

    Bladder Cancer Trial in France (Atezolizumab)

    Recruiting
    • Bladder Cancer
    • Bordeaux, France
    • +13 more
    Jul 5, 2022

    Patients With High-risk MIBC Trial in France (pelvic radiotherapy)

    Recruiting
    • Patients With High-risk MIBC
    • pelvic radiotherapy
    • Amiens, France
    • +26 more
    Oct 24, 2022

    Bladder Cancer Trial in Canada (Durvalumab, Immune Modulating Radiation)

    Recruiting
    • Bladder Cancer
    • Edmonton, Alberta, Canada
    • +3 more
    Jun 14, 2021

    Muscle Invasive Bladder Cancer Trial in Worldwide (AZD4547, MEDI4736, Olaparib)

    Active, not recruiting
    • Muscle Invasive Bladder Cancer
    • Los Angeles, California
    • +26 more
    Oct 17, 2022

    Predicting Post-cystectomy Outcome in Muscle Invasive Bladder

    Recruiting
    • Bladder Cancer
    • develop and validate a deep learning radiomics model based on preoperative enhanced CT image
    • Chongqing, Chongqing, China
      Department of Urology, The First Affiliated Hospital of Chongqin
    Oct 18, 2023

    Clinical Performance Evaluation of the C2i Test

    Not yet recruiting
    • Muscle Invasive Bladder Cancer
    • C2i-WGS-MRD Test
    • (no location specified)
    May 5, 2023

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Urinary Bladder Tumors Trial in Worldwide (Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy

    Recruiting
    • Urinary Bladder Neoplasms
    • Washington, District of Columbia
    • +120 more
    Jan 19, 2023

    AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication

    Recruiting
    • Muscle-Invasive Bladder Carcinoma
    • GAG score
    • Roskilde, Denmark
    • +2 more
    Jun 21, 2022